EAM
DRNA

EverPoint Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

EverPoint Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-25,000
Closed -$601K – 627
2015
Q1 		$601K Buy
+25,000
New +$562K 0.01% 476

Other funds holding DRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

EverPoint Asset Management's DRNA Position: Q2 2015 in Review

EverPoint Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2015, closing a stake of 25,000 shares — an estimated $601K sold.

EverPoint Asset Management first reported a position in DRNA in Q1 2015 and held it in 1 quarter. The position peaked at $601K in Q1 2015. 67 funds tracked by Wall St. Rank hold DRNA as of Q2 2015.

  • EverPoint Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
  • EverPoint Asset Management sold 25,000 Dicerna Pharmaceuticals, Inc. shares in Q2 2015, an estimated $601K.
  • EverPoint Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2015 and held it in 1 quarter.
  • EverPoint Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $601K in Q1 2015.
  • 67 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2015.

Based on EverPoint Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.